COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,300 Articles (22,772 medRxiv, 8,528 bioRxiv)

Most recent first Previous |  Page 1384: Articles 13831-13840  | Next

Understanding COVID-19 vaccine hesitancy in Pakistan: The paradigm of Confidence, Convenience and Complacency; A Cross-sectional study.
Sheikh, N. S., Touseef, M., Sultan, R., Cheema, K. H., Cheema, S. S., Sarwar, A., Siddique, H. Z.
10.1101/2021.07.12.21260409 — Posted: 2021-07-14
Case-control study of neuropsychiatric symptoms following COVID-19 hospitalization in 2 academic health systems
Castro, V., Rosand, J., Giacino, J., McCoy, T., Perlis, R. H.
10.1101/2021.07.09.21252353 — Posted: 2021-07-14
Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region
Liu, Y., Sandmann, F. G., Barnard, R. C., Pearson, C. A. B., LSHTM CMMID COVID-19 Working Group, , Pastore, R., Pebody, R., Flasche, S., Jit, M.
10.1101/2021.07.09.21260272 — Posted: 2021-07-14
Interaction between SARS-CoV-2 spike glycoprotein and human skin models: a molecular dynamics study
Domingo, M., Faraudo, J.
10.1101/2021.07.13.452154 — Posted: 2021-07-13
Analysis of amino acid change dynamics reveals SARS-CoV-2 variant emergence
Bernasconi, A., Mari, L., Casagrandi, R., Ceri, S.
10.1101/2021.07.12.452076 — Posted: 2021-07-13
A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines
Wang, H., Wu, X., Zhang, Y., Chen, Q., Dai, L., Chen, Y., Liu, X.
10.1101/2021.07.13.452194 — Posted: 2021-07-13
Development Of The Inactivated QazCovid-In Vaccine: Protective Efficacy Of The Vaccine In Syrian Hamsters
Zhugunissov, K., Zakarya, K., Khairullin, B., Orynbayev, M., Abduraimov, Y., Kassenov, M., Sultankulova, K., Kerimbayev, A., Nurabayev, S., Myrzhakhmetova, B., Nakhanov, A., Nurpeisova, A., Chervyakova, O., Assanzhanova, N., Burashev, Y., Mambetaliev, M., Azanbekova, M., Kopeyev, S., Kozhabergenov, N., Issabek, A., Tuyskanova, M., Kutumbetov, L.
10.1101/2021.07.13.452175 — Posted: 2021-07-13
Probing remdesivir nucleotide analogue insertion to SARS-CoV-2 RNA dependent RNA polymerase in viral replication
Romero, M. E., Long, C., La Rocco, D., Keerthi, A. M., Xu, D., Yu, J.
10.1101/2021.07.12.452099 — Posted: 2021-07-13 Discussion: Onsite
Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
Grandi, A., Tomasi, M., Accordini, S., Bertelli, C., Vanzo, T., Gagliardi, A., Caproni, E., Tamburini, S., Fantappie, L., Di Lascio, G., Bisoffi, Z., Piubelli, C., Valenti, M. T., Dalle Carbonare, L., Zipeto, D., Rava, M., Fumagalli, V., Di Lucia, P., Marotta, D., Sala, E., Iannacone, M., Cherepanov, P., Bolognesi, M., Pizzato, M., Grandi, G.
10.1101/2021.07.12.452027 — Posted: 2021-07-13
TNF-α levels in respiratory samples are associated with SARS-CoV-2 infection.
Pereson, M. J., Badano, M. N., Aloisi, N., Chuit, R., Braco, M. M., Bare, P.
10.1101/2021.07.12.452071 — Posted: 2021-07-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).